Login to Your Account



FDA denies Eisai, UCB efforts to tweak exclusivity timing

By Michael Fitzhugh
Staff Writer

Tuesday, May 6, 2014
The FDA has denied citizen's petitions filed by Eisai Inc. and UCB Inc. to change how the agency sets the five-year exclusivity clock for new chemical entities (NCEs) that require Controlled Substances Act (CSA) scheduling, stating that the approach the petitioners suggested is unworkable under current regulations.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription